IN2015DN02349A - - Google Patents

Download PDF

Info

Publication number
IN2015DN02349A
IN2015DN02349A IN2349DEN2015A IN2015DN02349A IN 2015DN02349 A IN2015DN02349 A IN 2015DN02349A IN 2349DEN2015 A IN2349DEN2015 A IN 2349DEN2015A IN 2015DN02349 A IN2015DN02349 A IN 2015DN02349A
Authority
IN
India
Prior art keywords
conjugates
specific
peptide
binding protein
drug
Prior art date
Application number
Inventor
Limited Polytherics
Original Assignee
Polytherics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/GB2013/051593 external-priority patent/WO2013190292A2/en
Application filed by Polytherics Ltd filed Critical Polytherics Ltd
Publication of IN2015DN02349A publication Critical patent/IN2015DN02349A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Specific conjugates containing auristatins and a binding protein or peptide and processes for making them are described. The conjugates use specific linker technology which gives advantages over known antibody drug conjugates. Also described are specific conjugates of drugs and a binding protein or peptide in which more than one copy of the drug is present.
IN2349DEN2015 2012-10-24 2013-10-11 IN2015DN02349A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261717743P 2012-10-24 2012-10-24
US201261717710P 2012-10-24 2012-10-24
US201361811285P 2013-04-12 2013-04-12
PCT/GB2013/051593 WO2013190292A2 (en) 2012-06-19 2013-06-19 Novel process for preparation of antibody conjugates and novel antibody conjugates
PCT/GB2013/052661 WO2014064423A1 (en) 2012-10-24 2013-10-11 Drug-protein conjugates

Publications (1)

Publication Number Publication Date
IN2015DN02349A true IN2015DN02349A (en) 2015-08-28

Family

ID=50544085

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2349DEN2015 IN2015DN02349A (en) 2012-10-24 2013-10-11

Country Status (19)

Country Link
US (2) US20150290342A1 (en)
EP (2) EP2911700B1 (en)
JP (1) JP6328648B2 (en)
KR (1) KR102209395B1 (en)
CN (1) CN104870021B (en)
AU (1) AU2013336409B2 (en)
BR (1) BR112015008376A2 (en)
CA (1) CA2884299A1 (en)
DK (1) DK2911700T5 (en)
ES (1) ES2623209T3 (en)
HK (1) HK1208187A1 (en)
IL (1) IL237672B (en)
IN (1) IN2015DN02349A (en)
MX (1) MX2015005122A (en)
MY (1) MY169147A (en)
RU (1) RU2015119561A (en)
SG (1) SG11201501618WA (en)
WO (1) WO2014064423A1 (en)
ZA (1) ZA201501642B (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2913732A1 (en) * 2013-06-04 2014-12-11 Cytomx Therapeutics, Inc. Compositions and methods for conjugating activatable antibodies
PT3057585T (en) 2013-10-15 2020-10-21 Seagen Inc Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics
WO2015179734A1 (en) * 2014-05-23 2015-11-26 Novartis Ag Methods for making conjugates from disulfide-containing proteins
KR102451080B1 (en) * 2014-06-12 2022-10-06 씨에스피씨 메가리스 바이오파마슈티칼 씨오., 엘티디. Homogeneous antibody drug conjugates via enzymatic methods
EP3218009B1 (en) 2014-10-14 2021-04-07 Polytherics Limited Process for the conjugation of a peptide or protein with a reagent comprising a leaving group including a portion of peg
WO2016063006A1 (en) * 2014-10-24 2016-04-28 Polytherics Limited Conjugates and conjugating reagents
GB201419108D0 (en) 2014-10-27 2014-12-10 Glythera Ltd Materials and methods relating to linkers for use in antibody drug conjugates
TWI660741B (en) 2015-11-03 2019-06-01 財團法人工業技術研究院 Antibody-drug conjugate (adc) and method for forming the same
MX2018006218A (en) 2015-12-04 2018-09-05 Seattle Genetics Inc Conjugates of quaternized tubulysin compounds.
US11793880B2 (en) 2015-12-04 2023-10-24 Seagen Inc. Conjugates of quaternized tubulysin compounds
WO2017161206A1 (en) 2016-03-16 2017-09-21 Halozyme, Inc. Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use
BR112018069273A2 (en) 2016-03-25 2019-01-22 Seattle Genetics Inc methods for preparing a compound and treating a subject with a hematological malignancy, compound, composition, and drug binding intermediate or drug binding compound
EP3442595A1 (en) 2016-04-14 2019-02-20 Polytherics Limited Conjugates and conjugating reagents comprising a linker that includes at least two (-ch2-ch2-0-) units in a ring
GB201608936D0 (en) 2016-05-20 2016-07-06 Polytherics Ltd Novel conjugates and novel conjugating reagents
CN109311996B (en) * 2016-06-06 2023-11-28 阿布泽纳(英国)有限公司 Antibodies, uses thereof and conjugates thereof
GB201614162D0 (en) * 2016-08-18 2016-10-05 Polytherics Ltd Antibodies, uses thereof and conjugates thereof
MX2019010769A (en) 2017-03-24 2019-12-11 Seattle Genetics Inc Process for the preparation of glucuronide drug-linkers and intermediates thereof.
GB201820864D0 (en) * 2018-12-20 2019-02-06 J A Kemp Antibody-drug conjugates
KR20230002672A (en) * 2020-04-15 2023-01-05 선전 엔듀어링 바이오테크 리미티드 Antibody-Drug Conjugates
AU2022237459A1 (en) * 2021-03-19 2023-09-21 Shenzhen Enduring Biotech, Ltd. Pegylated t cell engager with dual specificities to cd3 and cd19
WO2023141855A1 (en) * 2022-01-27 2023-08-03 Glyco-Therapy Biotechnology Co., Ltd. Protein conjugates with multiple payloads and methods for making the same

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0316294D0 (en) 2003-07-11 2003-08-13 Polytherics Ltd Conjugated biological molecules and their preparation
DK1725249T3 (en) 2003-11-06 2014-03-17 Seattle Genetics Inc Monomethylvaline compounds capable of conjugating to ligands.
EA016577B1 (en) * 2005-09-26 2012-06-29 Медарекс, Инк. Antibody-drug conjugates and use thereof
PT2211904T (en) * 2007-10-19 2016-11-02 Seattle Genetics Inc Cd19 binding agents and uses thereof
ES2647927T3 (en) 2008-03-18 2017-12-27 Seattle Genetics, Inc. Auriestatin drug linker conjugates
BRPI0911442A2 (en) * 2008-04-30 2019-03-12 Immunogen, Inc. potent conjugates and hydrophilic binders
EP2403538B1 (en) 2009-03-04 2017-10-04 Polytherics Limited Conjugated proteins and peptides
WO2010120561A1 (en) * 2009-04-01 2010-10-21 Genentech, Inc. Anti-fcrh5 antibodies and immunoconjugates and methods of use
UY32913A (en) * 2009-10-02 2011-04-29 Sanofi Aventis NEW MAITANSINOIDS AND THE USE OF SUCH MAITANSINOIDS TO PREPARE CONJUGATES WITH AN ANTIBODY
EP2841958A1 (en) * 2012-04-25 2015-03-04 Koninklijke Philips N.V. System and method for locating a gradient coil.
KR20150023027A (en) * 2012-06-19 2015-03-04 폴리테릭스 리미티드 Novel Process for Preparation of Antibody Conjugates and Novel Antibody Conjugates

Also Published As

Publication number Publication date
AU2013336409B2 (en) 2017-08-03
KR102209395B1 (en) 2021-01-28
DK2911700T3 (en) 2017-05-15
SG11201501618WA (en) 2015-04-29
BR112015008376A2 (en) 2017-09-26
HK1208187A1 (en) 2016-02-26
JP6328648B2 (en) 2018-05-23
RU2015119561A (en) 2016-12-20
AU2013336409A1 (en) 2015-04-02
EP3159013A1 (en) 2017-04-26
KR20150103656A (en) 2015-09-11
IL237672A0 (en) 2015-04-30
ES2623209T3 (en) 2017-07-10
WO2014064423A1 (en) 2014-05-01
IL237672B (en) 2018-02-28
MY169147A (en) 2019-02-18
CN104870021A (en) 2015-08-26
JP2015533847A (en) 2015-11-26
MX2015005122A (en) 2015-10-29
EP2911700B1 (en) 2017-02-08
US20150290342A1 (en) 2015-10-15
ZA201501642B (en) 2016-01-27
US20220062436A1 (en) 2022-03-03
CN104870021B (en) 2018-03-13
EP2911700A1 (en) 2015-09-02
CA2884299A1 (en) 2014-05-01
DK2911700T5 (en) 2017-05-22

Similar Documents

Publication Publication Date Title
IN2015DN02349A (en)
CY1122490T1 (en) ANTIBODIES TO HUMAN CD38
MX2015005124A (en) Drug-protein conjugates.
MY168297A (en) Cytotoxic Peptides and Antibody Drug Conjugates Thereof
PH12015500390B1 (en) Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis
EA201691023A1 (en) PEPTIDOMIMETIC CONNECTIONS AND THEIR CONJUGATES ANTIBODIES WITH MEDICINE
TN2013000245A1 (en) Antitumor combinations containing antibodies recognizing specifically cd38 and bortezomib
TN2015000396A1 (en) Antibody drug conjugates
NZ703581A (en) Anti-cd70 antibody drug conjugates
NZ630542A (en) Methods of treating a tauopathy
MX2015012122A (en) Antibody drug conjugates and corresponding antibodies.
UA113712C2 (en) FAP ANTIBODY AND METHODS OF ITS APPLICATION
TN2011000232A1 (en) Antitumor combinations containing antibodies recognizing specifically cd38 melphalan
MX340062B (en) Antitumor combinations containing antibodies recognizing specifically cd38 and cylophosphamide.
PH12018500159A1 (en) Constructs targeting psa peptide/mhc complexes and uses thereof
MX2013002718A (en) Anti-vegfr-3 antibody compositions.
MX2013003168A (en) Anti-ephrin-b2 antibody and use thereof.
TN2013000068A1 (en) Anti-vegfr-3 antibody compositions
TN2011000153A1 (en) Antitumor combinations containing antibodies recognizing specifically cd38 and cylophosphamide